Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Medinotec (MDNC) Liabilities and Shareholders Equity (2022 - 2025)

Historic Liabilities and Shareholders Equity for Medinotec (MDNC) over the last 4 years, with Q4 2025 value amounting to $6.9 million.

  • Medinotec's Liabilities and Shareholders Equity rose 2779.06% to $6.9 million in Q4 2025 from the same period last year, while for Nov 2025 it was $27.4 million, marking a year-over-year increase of 3868.0%. This contributed to the annual value of $6.8 million for FY2025, which is 4172.73% up from last year.
  • According to the latest figures from Q4 2025, Medinotec's Liabilities and Shareholders Equity is $6.9 million, which was up 2779.06% from $6.4 million recorded in Q3 2025.
  • Over the past 5 years, Medinotec's Liabilities and Shareholders Equity peaked at $7.4 million during Q2 2025, and registered a low of $1.3 million during Q1 2022.
  • Its 4-year average for Liabilities and Shareholders Equity is $5.1 million, with a median of $5.0 million in 2022.
  • Data for Medinotec's Liabilities and Shareholders Equity shows a peak YoY increase of 23940.49% (in 2023) and a maximum YoY decrease of 2160.76% (in 2023) over the last 5 years.
  • Over the past 4 years, Medinotec's Liabilities and Shareholders Equity (Quarter) stood at $5.1 million in 2022, then fell by 21.61% to $4.0 million in 2023, then surged by 34.34% to $5.4 million in 2024, then grew by 27.79% to $6.9 million in 2025.
  • Its Liabilities and Shareholders Equity stands at $6.9 million for Q4 2025, versus $6.4 million for Q3 2025 and $7.4 million for Q2 2025.